Medifast (MED) Common Equity (2010 - 2026)

Medifast has reported Common Equity for 17 years, with the latest figure at $197.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 6.29% year-over-year to $197.7 million; the trailing twelve-month figure through Mar 2026 stood at $197.7 million (down 6.29% YoY), and the FY2025 full-year result was $198.9 million, down 5.33% from the prior year.
• Common Equity for Q1 2026 stood at $197.7 million, down from $198.9 million in the prior quarter.
• The five-year high for Common Equity was $216.0 million in Q1 2022, with the low at $129.5 million in Q2 2022.
• Historically, Common Equity has averaged $192.6 million across 5 years, with a median of $201.5 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity sank 33.5% — and 2023, when it soared 43.32%.
• Medifast's Common Equity stood at $155.0 million in 2022, then increased by 29.95% to $201.5 million in 2023, then rose by 4.28% to $210.1 million in 2024, then dropped by 5.33% to $198.9 million in 2025, then dropped by 0.62% to $197.7 million in 2026.
• The last three Common Equity figures came in at $197.7 million (Q1 2026), $198.9 million (Q4 2025), and $214.7 million (Q3 2025), per Business Quant data.